Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Sponsor: Case Comprehensive Cancer Center

Purpose

To find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding NR to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment.

Study Design

Single group assignment, open label

Dose

500mg 2x daily for 21, 28, and 35 days

Length of Intervention

Up to 35 days

Intrinsic Capacity

Vitality

Status

Not Yet Recruiting

Condition or Disease 

Allogeneic Hematopoietic Cell Transplantation

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Cancer, ClinicalANAD StaffCancer